InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.03
(
-0.12%
)
Bitcoin
64,077.50
(
0.12%
)
Post# of 14671
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NoMoDo

Send PM Follow Ignore
Followers 148
Posts 7871
Boards Moderated 2
Alias Born 03/15/2002

NoMoDo

Member Level

Re: None

Tuesday, 04/23/2002 1:14:53 PM

Tuesday, April 23, 2002 1:14:53 PM

Post# of 14671
Nova BioGenetics Receives 'Chinese Department of Health' Approval (FDA Equivalent) for Antimicrobial Hand Gel


Nova BioGenetics Receives First Distribution Agreement for Its Medical

Products in Hospitals and Other Medical Applications

ATLANTA, April 23 /PRNewswire-FirstCall/ -- BioShield Technologies, Inc. (OTC Bulletin Board: BSTI) announced today that Nova BioGenetics, an affiliate company of BioShield, has recently received approval from the Chinese Government's Department of Health for the country's first Antimicrobial Hand Gel using Bioshield's Technology.

Through Nova BioGenetics and BioShield's partnership with MegaStar Universal, Ltd., Megastar has been very active in formulating, testing and creating China's first Antimicrobial Hand Gel approved by the Chinese FDA using Bioshield's patented technology. Initial marketing of the product in China and Asia has produced significant demand and medical acceptance for the product as it mitigates the vast majority of the bacteria and fungi that typically create viral illnesses.

Tim Moses, CEO for BioShield, stated, "We have worked on this project for quite some time and Megastar has made significant investments in China to build a plant to facilitate the manufacture of various health based consumable items and Health Department based products. This significant event is an amazing feat for Nova BioGenetics and receiving the FDA mark of China is the first of many endeavours Nova Biogenetics will make to further advance the FDA side of BioShield's technology both in the United States and abroad. Having this approval and Megastar launching China's first antimicrobial Hand Gel is the first product of a line of products to be introduced during the coming years and we believe this will help with the rapid development of new Nova Biogenetics based products with other partners and countries in the very near future. We anticipate initial orders from Megastar to support demand for this product to start coming in the near future."

ABOUT BIOSHIELD

BioShield Technologies, Inc., is a Georgia-based biotechnology and antimicrobial products company. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is a revolutionary alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria, including HIV, on contact and can remain active for extended time periods. To date BioShield has received three US patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and stormwater.

Further information on BioShield and its line of products can be found by visiting the firm's web site at http://www.bioshield.com , or by calling 1- 770-925-3653. Contact Timothy Moses.

Safe Harbor/Forward-looking Statements

Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of BioShield; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. BioShield does not undertake to revise or update any forward-looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of BioShield Technologies, Inc.

it only gets better.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up